On the expense side, we anticipate epacadostat and baricitinib to be drivers of ongoing R&D expense, and the recently signed agreements with Agenus, Merus and Calithera will add one-time items to our R&D expense in 2017. In terms of SG&A expense, 2017 will be the first full year that we include our European operations